Browsing Tag
J.P. Morgan
54 posts
Can Payward turn the Bending Spoons IPO into tokenized equities’ breakout moment?
Payward Services is extending Bending Spoons IPO participation to eligible Kraken and xStocks users outside the United States, but BSPx will test whether tokenization can improve primary-market distribution without reproducing the exclusions and risks of traditional finance.
Jamie Dimon is still in charge, so why has JPMorgan intensified its succession contest?
Doug Petno and Troy Rohrbaugh now control JPMorgan Chase’s two largest businesses, sharpening the succession contest around Jamie Dimon while Marianne Lake’s retirement removes one of the bank’s most experienced leaders.
Innodata’s new CFO inherits a booming AI business and a valuation with little room for error
Innodata names Jayant Chauhan CFO as AI growth accelerates. See how finance discipline, M&A expertise and valuation pressure could shape its next phase now.
Is Super Micro Computer’s $7bn raise a growth signal or a dilution warning for SMCI?
Find out why Super Micro Computer’s $7bn AI financing plan hit SMCI stock despite a $39bn order backlog and strong server demand.
Is the SpaceX IPO a Starlink growth story or an AI valuation gamble dressed as a rocket stock?
Find out how SpaceX’s record IPO could shape SPCX stock sentiment, Starlink valuation, AI risks, and retail investor appetite.
Did Tango Therapeutics Inc. just turn one cancer data shock into a $600m runway?
Find out how Tango Therapeutics Inc.'s $600 million offering could reshape TNGX sentiment, dilution risk, and its oncology runway.
Quantinuum IPO closes at $1.68bn, but QNT trading shows investors want proof beyond quantum hype
Quantinuum raised $1.68bn, but QNT’s early trading asks the real question: can quantum computing turn promise into revenue?
Tega Industries completes $1.5bn Molycop acquisition with Apollo Funds as TEGA scales global mining consumables platform
Tega now controls Molycop, but the USD 1.5bn deal’s real test is integration. Read how TEGA could reshape mining consumables.
Delivery Hero (DHER) stock up 4% to €29.5 as Aspex forces CEO exit and Korea sale opens
Aspex pushed out the CEO and bought 5% more. Prosus must keep selling. Korea is on the block. Delivery Hero (XETRA: DHER) is being rebuilt in real time.
Catalyst Pharmaceuticals (CPRX) agrees $4.1bn buyout as Angelini Pharma plans to enter US rare disease market
Angelini Pharma will pay $4.1 billion for Catalyst Pharmaceuticals at $31.50 a share, but CPRX closed at $31.10. The premium sits in the strategy, not the price.